Evaluation of plasma biomarkers measured at the time of diagnosis for prediction of therapeutic response
| Marker . | N . | Responder* . | N . | Non responder . | Mean difference (95% CI) . | P . |
|---|---|---|---|---|---|---|
| sCD13, units/mL | 16† | 0.037 | 19 | 0.016 | −.007 (−.023; .008) | 0.34 |
| sIL2Rα, pg/mL | 19 | 7612 | 21 | 11 010 | −3398 (6450; 346) | 0.03 |
| sBAFF, pg/mL | 18† | 7635 | 19 | 6620 | 1015 (−2572; 4602) | 0.57 |
| Anti-dsDNA, IU/mL | 19 | 2.7 | 21 | 3.2 | −.52 (−2.41; 1.37) | 0.58 |
| Marker . | N . | Responder* . | N . | Non responder . | Mean difference (95% CI) . | P . |
|---|---|---|---|---|---|---|
| sCD13, units/mL | 16† | 0.037 | 19 | 0.016 | −.007 (−.023; .008) | 0.34 |
| sIL2Rα, pg/mL | 19 | 7612 | 21 | 11 010 | −3398 (6450; 346) | 0.03 |
| sBAFF, pg/mL | 18† | 7635 | 19 | 6620 | 1015 (−2572; 4602) | 0.57 |
| Anti-dsDNA, IU/mL | 19 | 2.7 | 21 | 3.2 | −.52 (−2.41; 1.37) | 0.58 |
Some patients did not have sufficient plasma sample volumes to allow analysis.
Responder was defined as either a partial response (PR) or complete response (CR) identified at 9 months after start of therapy and non responder was defined as a mixed or non response at 9 months.
Patients that were not evaluable (N = 12) due to removal from therapy due to progressive disease, infection, toxicity, parent or physician preference or relapse of malignancy were excluded in the analysis.